Pioneering pain management with botulinum toxin type A: From anti-inflammation to regenerative therapies

In the present paper, a comprehensive review was conducted to evaluate the performance of botulinum toxin type A (BTX-A) in managing various types of pain, including myofascial, muscular temporomandibular joint pain, orofacial pain, chronic migraines, and more. Firstly, the mechanism of action and anti-inflammatory effects of BTX-A was introduced. Following this, recent advancements in BTX-A applications were discussed, with an emphasis on emerging combination therapies, regenerative medicine, and personalized treatment strategies. Unlike previous reviews, this study explored a broader spectrum of pain conditions and highlighted BTX-A's versatility and potential as a long-term, minimally invasive pain management option. Additionally, the importance of tailoring BTX-A treatment was emphasized through the integration of biomarkers, genetic factors, and optimized dosing regimens to enhance efficacy and minimize side effects. Novel combinations with regenerative therapies, such as stem cells and tissue engineering, were identified as promising avenues for joint and nerve repair, providing both symptomatic relief and tissue regeneration. Furthermore, digital health tools and artificial intelligence were suggested as innovative approaches to monitor treatment responses and optimize dosing protocols in real-time, advancing personalized pain management. Overall, this review underscores BTX-A's potential in comprehensive and patient-centered pain management and offers recommendations to guide future studies in optimizing BTX-A therapy.